Stockscreener 앱 받기
2.69
1.89%
0.05
시장 영업 전:
3.10
0.41
+15.24%
전일 마감가:
$2.64
열려 있는:
$2.64
하루 거래량:
814.98K
Relative Volume:
0.78
시가총액:
$126.72M
수익:
$138.90M
순이익/손실:
$-107.15M
주가수익비율:
-1.0661
EPS:
-2.5232
순현금흐름:
$-79.85M
1주 성능:
-2.18%
1개월 성능:
-17.48%
6개월 성능:
-59.61%
1년 성능:
-44.31%
1일 변동 폭
$2.61
$2.80
1주일 범위
$2.395
$2.83
52주 변동 폭
$2.395
$8.77
Quanterix Corp Stock (QTRX) Company Profile
명칭
Quanterix Corp
전화
617-301-9400
주소
900 MIDDLESEX TURNPIKE, BILLERICA, MA
Compare QTRX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QTRX
Quanterix Corp
|
2.69 | 124.36M | 138.90M | -107.15M | -79.85M | -2.5232 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Quanterix Corp Stock (QTRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-11 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-02-01 | 개시 | Scotiabank | Sector Outperform |
| 2023-09-25 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-08 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-05-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-15 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-08-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-08-09 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-03-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-04 | 개시 | Goldman | Sell |
모두보기
Quanterix Corp 주식(QTRX)의 최신 뉴스
Quanterix targets $169M-$174M 2026 revenue while preparing HD-X IVD filing in 2027 - MSN
Quanterix (QTRX) CFO reports RSU vesting and tax-withholding share dispositions - Stock Titan
Quanterix (QTRX) CTO gains 1,558 shares from RSU vesting, 467 withheld for tax - Stock Titan
Quanterix Corp stock (US74876Y1001): Analyst price target raised while shares trade near lows - AD HOC NEWS
Portolan Capital, George McCabe report 6.25% stake in Quanterix (QTRX) - Stock Titan
Quanterix (NASDAQ: QTRX) — Ameriprise reports 3,542,374 shared votes - Stock Titan
QTRX Technical Analysis | Trend, Signals & Chart Patterns | QUANTERIX CORP (NASDAQ:QTRX) - ChartMill
Quanterix stock (US74876Y1001): Biotech diagnostics firm faces headwinds amid guidance revision - AD HOC NEWS
AMERIPRISE FINANCIAL INC Significantly Reduces Stake in Quanteri - GuruFocus
Quanterix (QTRX) Announces CFO Departure and Transition Plans - GuruFocus
Quanterix CFO Vandana Sriram to depart in June - Investing.com
Quanterix CFO Michael J. Doyle to Depart on July 3, 2026; Search for Successor Begins - geneonline.com
Quanterix (QTRX) CFO Vandana Sriram to depart in June 2026 after planned transition - Stock Titan
Quanterix finance chief to depart after June 15 handover - Stock Titan
TradingKey - TradingKey
MSN Money - MSN
Quanterix (NASDAQ:QTRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Quanterix Corporation 2026 Q1 Financials: Akoya Acquisition, Revenue Performance & Forward-Looking Statements - Minichart
QTRX Maintained by TD Cowen -- Price Target Lowered to $4.00 - GuruFocus
Q1 2026 Quanterix Corp Earnings Call Transcript - GuruFocus
Earnings call transcript: Quanterix Q1 2026 EPS beats, revenue misses By Investing.com - Investing.com India
Quanterix CEO Everett Cunningham Highlights Market Leadership in Earnings Call - HarianBasis.co
Ameriprise Financial (NASDAQ: QTRX) reports 990,224 shares, 2.1% stake - Stock Titan
Quanterix Q1 Earnings Call Highlights - Yahoo Finance
Quanterix Q1 2026 slides: $85M synergies offset organic decline - Investing.com
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: Quanterix Q1 2026 EPS beats, revenue misses - Investing.com
Quanterix (NASDAQ:QTRX) Beats Q1 2026 EPS Estimates Despite Revenue Miss - ChartMill
Quanterix (NASDAQ: QTRX) grows revenue 20% but books $19.3M impairment - Stock Titan
QUANTERIX ($QTRX) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Quanterix (NASDAQ: QTRX) grows Q1 revenue 20% and keeps 2026 outlook - Stock Titan
Quanterix keeps 2026 outlook, eyes FDA decision on Alzheimer’s test - Stock Titan
Quanterix partners with Tempus AI on Alzheimer’s blood test - Investing.com
Quanterix Corp expected to post a loss of 54 cents a shareEarnings Preview - TradingView
How The Quanterix (QTRX) Story Is Shifting After The Latest Fair Value Reset - Yahoo Finance
Quanterix (QTRX) COO logs RSU conversion and small tax share disposal - Stock Titan
Quanterix rises on CMS price for LucentAD Alzheimer blood biomarker test - MSN
Quanterix (QTRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Quanterix (QTRX) price target decreased by 13.33% to 6.63 - MSN
Quanterix schedules after-close Q1 results, 4:30 p.m. ET call - Stock Titan
[ARS] Quanterix Corp SEC Filing - Stock Titan
Quanterix (NASDAQ: QTRX) details 2026 virtual meeting and pay votes - Stock Titan
Quanterix Corp (QTRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
1.41%
자본화:
|
볼륨(24시간):